Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T86399
|
||||
Former ID |
TTDI02030
|
||||
Target Name |
Bromodomain-containing protein 2
|
||||
Gene Name |
BRD2
|
||||
Synonyms |
O27.1.1; Really interesting new gene 3 protein; BRD2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Myelodysplastic syndrome [ICD9: 238.7; ICD10: D46] | ||||
Function |
May play a role in spermatogenesis or folliculogenesis (By similarity). Binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling. Regulates transcription ofthe CCND1 gene. Plays a role in nucleosome assembly. {ECO:0000250, ECO:0000269|PubMed:18406326}.
|
||||
BioChemical Class |
Bromodomain
|
||||
UniProt ID | |||||
Sequence |
MLQNVTPHNKLPGEGNAGLLGLGPEAAAPGKRIRKPSLLYEGFESPTMASVPALQLTPAN
PPPPEVSNPKKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQP MDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDDIVLMAQTLEKIFLQKVASM PQEEQELVVTIPKNSHKKGAKLAALQGSVTSAHQVPAVSSVSHTALYTPPPEIPTTVLNI PHPSVISSPLLKSLHSAGPPLLAVTAAPPAQPLAKKKGVKRKADTTTPTPTAILAPGSPA SPPGSLEPKAARLPPMRRESGRPIKPPRKDLPDSQQQHQSSKKGKLSEQLKHCNGILKEL LSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRL MFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPDEPLEPGPLPVSTAMPPGLAKSSSES SSEESSSESSSEEEEEEDEEDEEEEESESSDSEEERAHRLAELQEQLRAVHEQLAALSQG PISKPKRKREKKEKKKKRKAEKHRGRAGADEDDKGPRAPRPPQPKKSKKASGSGGGSAAL GPSGFGPSGGSGTKLPKKATKTAPPALPTGYDSEEEEESRPMSYDEKRQLSLDINKLPGE KLGRVVHIIQAREPSLRDSNPEEIEIDFETLKPSTLRELERYVLSCLRKKPRKPYTIKKP VGKTKEELALEKKRELEKRLQDVSGQLNSTKKPPKKANEKTESSSAQQVAVSRLSASSSS SDSSSSSSSSSSSDTSDSDSG |
||||
Drugs and Mode of Action | |||||
Inhibitor | BIC1 | Drug Info | [531444] | ||
compound 36 | Drug Info | [532467] | |||
compound 38 | Drug Info | [532467] | |||
compound 4d | Drug Info | [531602] | |||
ET bromodomain inhibitor | Drug Info | [532995] | |||
GW841819X | Drug Info | [531473] | |||
I-BET151 | Drug Info | [531641] | |||
ME bromodomain inhibitor | Drug Info | [532995] | |||
XD14 | Drug Info | [532562] | |||
Modulator | OTX-015 | Drug Info | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Regulation of retinoblastoma protein | ||||
WikiPathways | Chemical Compounds to monitor Proteins | ||||
References | |||||
Ref 531444 | Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol. 2011 Apr 22;18(4):495-507. | ||||
Ref 531473 | Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38. | ||||
Ref 531602 | 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70. | ||||
Ref 531641 | Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. | ||||
Ref 532467 | Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.